# FDA recall D-1099-2018

> **Orexigen Therapeutics, Inc.** · Class III · drug recall initiated 2018-08-09.

## Product

Contrave (naltrexone HCl and bupropion HCl) Extended-Release Tablets, 8 mg/90 mg, 120-count bottle, Rx only, Distributed by Orexigen therapeutics, Inc., La Jolla, CA  92037, NDC 51267-890-99.

## Reason for recall

Defective Container: Customer complaints of punctures in the bottle.

## Distribution

Nationwide in the USA

## Key facts

- **Recall number:** D-1099-2018
- **Recalling firm:** Orexigen Therapeutics, Inc.
- **Classification:** Class III
- **Product type:** drug
- **Status:** Terminated
- **Initiation date:** 2018-08-09
- **Report date:** 2018-08-22
- **Termination date:** 2019-11-15

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** La Jolla, CA, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-1099-2018

## Citation

> AI Analytics. FDA recall D-1099-2018. Retrieved 2026-06-02 from https://api.ai-analytics.org/recall/D-1099-2018. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*